Together, these data indicate that PTPN22-deficient CD8+ memory T cells retain their enhanced functional characteristics and are superior in their capacity to provide long-lived protection from tumor growth in response to both high- and low-affinity tumor antigens in vivo, as compared with control T cells. This evidence concerns the gene CD8A and neoplasm.